Business
Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)
Toronto, Ontario--(Newsfile Corp. - June 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: T...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)Toronto, Ontario--(Newsfile Corp. - June 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (\"Therma\" or the \"Company\"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its Health Canada application for the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point-of-Care Use (PoC). The HC application includes all the updated data from the Company's U.S. Food and Drug Administration's Emergency Use Authorization (EUA) application. \"We're excited with our AcuVid™ Health Canada application and the prospect of approval for our unique COVID-19 rapid antigen saliva test for point-of-care (PoC),\" shared Rob Fia, CEO of Therma Bright. \"While we wait for both the U.S. FDA Emergency Use Authorization (EUA) and Health Canada review and approval, our team has begun preparing other regulatory applications where we believe our AcuVid™ COVID-19 Rapid Antigen Saliva Test will be in high demand this fall when countries from around the globe expect a resurgence of Covid-19.\"Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.About Therma Bright Inc.Therma Bright, developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the U.S. FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com. Therma Bright Inc.Rob Fia, CEO [email protected] us on Twitter...